For postmenopausal women with non-metastatic hormone receptor-positive
breast cancer who have completed a five-year course of an aromatase inhibitor (AI), the authors of UpToDate’s ‘Practice Changing
recommend continuing the AI for an additional five years (Grade 2A evidence). However, it is reasonable for women with low risk
of recurrence who are concerned about the risks and toxicities of extended treatment to omit extended treatment after a risk-benefit discussion.